Medizone Intl. (fka MZEIQ)

[Tane61]

Application Of Ozone To External Body Surfaces:

Why would Medizone even consider implementing this patented (Sunnen, U.S. Pat. No. 6,073,627) ozone based technology when the inventor himself outlined, in a subsequent patent application (filed April 2005), shortcomings in respect of it's potential for effective application in the REAL WORLD?

http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20060241549.PGNR.

[0080] A previous invention (Sunnen, U.S. Pat. No. 6,073,627) included a transparent envelope with inserted sensors for ozone concentration, humidity, and patient temperature located within the treatment envelope, each relaying data to a display on the ozone generator panel.

[0081] Previous art such as U.S. Pat. No. 6,073,627 attempted to address this issue. This art described an ozone generator which delivered an ozone/oxygen mixture into a treatment envelope encasing the patient's lesion. The problem of delivering a precise ozone/oxygen mixture, however, was only partially solved by this art, based upon the following considerations:

[0082] 1. The ozone concentration within the treatment envelope was relayed to a readout gauge on the ozone generator, to be read by the clinical personnel. In order to maintain a constant ozone concentration over time and thus adhere to a precise treatment protocol, the personnel would be obliged not only to be present during the entire treatment process but also to adjust the generator's output in response to the fluctuations normally observed in intra-envelope ozone concentrations. [0083] It would therefore be desirable to have a delivery system with an automatic microprocessor-mediated feedback of intra-envelope ozone concentrations in order to counteract their fluctuations in a timely fashion.

[0084] 2. The temperature of the patient was monitored, but the temperature inside the treatment envelope was not. Intra-envelope ambient temperature is an integral part of the treatment protocol of external wounds with ozone/oxygen. Indeed, some dermatological lesions, such as frostbite, require higher therapeutic ambient temperatures while others do not. Furthermore, temperature itself has an influence upon ozone concentration, with lower temperatures associated with higher concentrations. [0085] It would therefore be desirable to provide a delivery system with a constant integration of ozone and temperature and an automatic microprocessor-mediated feedback of intra-envelope temperature to achieve temperature-to-ozone constancy.

[0086] 3. Intra-envelope humidity influences ozone concentration, with higher ozone output by the generator needed at higher humidity levels to maintain a constant ozone concentration. The therapy of dermatological conditions requires attention to the maintenance of intra-envelope humidity levels. Some lesions, such as wet gangrene, must be kept dry, while others need moisture. This invention may comprise an automatic microprocessor-mediated regulation of humidity levels to achieve constancy of the intra-envelope humidity milieu.

[0087] 4. The space within the treatment envelope can show significant regional variations and fluctuations in ozone concentration, temperature, and humidity, depending upon the placement of probes and the unavoidable presence of pockets of "dead space." This invention may comprise an intra-envelope fan to homogenize the ambient ozone/oxygen mixture so that probe readings will be accurate.

[0088] 5. Treatment envelopes in U.S. Pat. No. 6,073,627 were mere plastic bags. They required careful adjustment to anatomical parts so as to minimize unnecessary dead space, offer patient convenience, and avoid apposition of the envelope sheath to the patient's tissues. Described herein are improved envelopes having rigid or flexible supporting ribs or other supporting structures which address these needs.

------------------------

MZEI does not need a repeat of this debacle:

MEDIZONE INTERNATIONAL INC

FORM 10-K/A

Filed 04/13/98 for the Period Ending 12/31/97

"In 1990, the Canadian Blood Forces Program (under the aegis of the Canadian Department of Defense and Agriculture and the Canadian Red Cross) requested that the Company add the Medizone Technology to the other proprietary technology being investigated as an experimental arm of an ozone- based blood sterilization investigative program. The program was an attempt to develop an effective technology for sterilizing whole blood and blood products. This program, which was to study the Medizone Technology as it relates to the inactivation of Simian Immunodeficiency Virus ("SIV"), included a live primate model.

"The program continued until 1994, completing two out of the three proposed stages, when the funding arm of the Canadian Blood Forces Program discontinued funding the program.

"The Company's current management learned in late 1997 that the program, as it involves the Medizone Technology, was stopped primarily due to an equipment failure and the generation of erroneous data due to the equipment failure.

"The third stage of the study was resumed in May 1996, but did not utilize the Medizone Technology."

------------------------

Ozone based technology for the treatment of non-healing wounds has been patented, manufactured and clinically trialled

QUOTE: "OZ Recovery Technologies is a start-up company that was established by engineer Dr. Vladimir Piuk, MDs Dr. Sergei Shnizer, and Dr. Nella Mizruhin with the participation of electronic engineer Mark Shnaiderman and L.N. Innovative Technologies Ltd.

"During the last 10 years OZ Recovery Technologies has developed a unique treatment for non-healing wounds, using a mixture of ozone and oxygen

"OZ Recovery Technologies introduces the Ozoter-101 — a new device and methodology for the healing of non-healing chronic wounds with the administration of an ozone-and-oxygen mixture directly to skin wounds.

"While the benefits of ozone therapy have been known and studied for over a century, technological limitations have until now hindered its application and proliferation.

"The Ozoter-101 is a breakthrough in the field, employing a proprietary new method for delivering the ozone to the wound site.

"OZ Technologies are protected by a portfolio of patents covering, inter alia, the treatment process and the control system."

http://oz-recovery.com/english/index.html